In the News

“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]

GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.

Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]

Washington, DC — December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that […]

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]

GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials.  Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted […]

GAP President, John Dwyer, spoke to Genome Web about the closing of our Bio-Hermes study, and what the results may do for the future of Alzheimer’s research. The Global Alzheimer’s Platform (GAP) has completed a first-of-its-kind cross sectional study comparing the performance of Alzheimer’s diagnostic assays. Topline results are expected in July of next year, […]

GAP-Net site, El Faro Health & Therapetuics was featured in AARP on the work they are doing to bring Alzheimer’s research to the Latino and Starr County communities. On a gloomy mid-November morning in 2021, Jessica Cantú stood in the parking lot outside a health center in the rural border community of Starr County, Texas, […]

The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global […]

The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]

WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as […]

WASHINGTON, DC, Sept. 28, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s disease, marking an enormous milestone for millions of people living with Alzheimer’s disease. The positive trial results, released by Eisai Tuesday night, show that the novel drug helped slow cognitive decline […]

GAP-Net Site El Faro Health and Therapeutics in Texas’ Starr County continues working to connect the area’s predominantly Hispanic community with access to Alzheimer’s research and health care. Washington, D.C. — Today, Global Alzheimer’s Platform Foundation (GAP) John Dwyer applauded the work that Dr. James Falcon and the whole El Faro Health and Therapeutics team […]

In honor of World Alzheimer’s Day, the Global Alzheimer’s Platform Foundation continues to push for diversity in Alzheimer’s clinical trials WASHINGTON, DC, Sept. 20, 2022 — In recognition of World Alzheimer’s Day (Sept. 21), the Global Alzheimer’s Platform Foundation (GAP) is bringing its mobile research unit into Orlando-area communities. This continues GAP’s work toward increasing participation of […]

GAP President John Dwyer spoke with Duane Schulthess on the Vital Health podcast about everything from the work that GAP is doing with the Davos Alzheimer’s Collaborative and the CEOI and the CMS decision several months ago. “It’s just a fact that there are a lot of us that are sick with Alzheimer’s. It is the […]

There was justifiable ink given last month in the media to the Lesné research misconduct. But it missed the mark. The real Alzheimer’s story is the “amyloid hypothesis” related to A?*56 is a small fraction of the research being done in an industry that is funding, backed by a lot of heart, to find a […]

GAP-Net Site, iResearch Atlanta, hosted an event to brainstorm ways to educate community members on Alzheimer’s and other dementia related diseases. Near the end of July, 10 individuals from the Global Alzheimer’s Platform Foundation (GAP), MapHabit, Collaborative Real Estate, and 250 E Ponce’s very own iResearch Atlanta were exclusively invited to gather over complimentary lunch […]

GAP partner, Genetech, is working with us on our Bio-Hermes study to increase diversity in Alzheimer’s clinical trials. Missing a trial goal in Alzheimer’s disease is a pretty common occurrence—see crenezumab, for the latest. But Genentech’s latest reported miss was something different. The Roche unit wanted to build a clinical trial program for its lead candidate […]

The new program will provide much-needed resources and workforce development opportunities for clinical trial sites challenged by a shortage of approved raters. WASHINGTON, DC, Aug.1 — The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational resources and training to support Alzheimer’s disease research. This will provide […]

Global Alzheimer’s Platform Foundation to present information about trial diversity at the Alzheimer’s Association International Conference. WASHINGTON, DC, July 27, 2022 — As a leading organization focused on increasing participant diversity in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation® (GAP) will present data at the Alzheimer’s Association International Conference® 2022 (AAIC®) to share information about its […]

Dr. Richard Holub from GAP-Net site Neurological Associates of Albany talks about his commitment to finding a cure for Alzheimer’s disease and says he won’t be retiring anytime soon. Dr. Richard Holub has spent the past 40 years dedicated to Alzheimer’s research. He has treated thousands of Alzheimer’s patients and completed more than 125 clinical […]

Individuals who are usually at risk of developing Alzheimer’s can take part in pre-screening visits at every mobile site stop. Global Alzheimer’s Platform Foundation (GAP) has introduced a new mobile health site to lower barriers to the participation of underrepresented communities in Alzheimer’s clinical trials. Around 1% of the African Americans and Hispanics with Alzheimer’s take part […]

Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer’s Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six […]

GAP-Net Site Brigham and Women’s Hospital Center for Alzheimer Research & Treatment (CART), was featured in their local news station about the importance of volunteer participation in clinical research. A local hospital is now part of a global effort to test a drug that may delay the devastating impact of Alzheimer’s disease. The progressive neurological […]